Good MorningEquities shrugged off another hot month of inflation data last week in favor of earnings. The S&P 500 moved up to set a new all-time high on Friday, the question now is whether or not the index can keep it. Along with inflation, the Delta covid variant has emerged as a real threat to the market and could have a serious impact on the second half of the year. Estimates for earnings continue to rise but the pace has slowed over the past week as a rising number of companies warn the market about the second-half outlook.
This week, the focus will be on the consumer. Not only are we expecting a read on retail sales but earnings reports from a host of major retailers including Home Depot and Walmart are due as well. The big-box retailers are expected to post slight YOY revenue declines in the face of last year's tough comparisons.
Featured: One Stock For A HUGE 2021 (Darwin) 
|
Stocks | | | It’s a bit surprising that capital markets stocks don’t attract more attention from investors and traders, especially given that these companies offer exchange marketplaces where financial securities can be bought and sold. Along with providing a way for traders to buy and sell things li... Read the Full Story |
|
|
Stocks | | | the top sports betting stocks have been underperformers thus far in 2021,, which means investors can grab shares while they are well off of their highs. There's also the fact that football season is set to kick off again in September and could be the perfect catalyst to get these stocks going again. Read the Full Story |
|
Politics | | | Asian shares slipped Monday, amid worries about surging coronavirus infections in the region, as well as concerns about the long-term impact from the Afghan government’s collapse.
Japan's benchmark Nikkei 225 sagged 1.7% to 27,502.21 in afternoon trading, while Australia's S&P/ASX... Read the Full Story |
|
From Our PartnersOften, a stock will become undervalued because of negative events, like the pandemic. Perhaps the company missed earnings, became overlooked, or was hit with downgrades. Whatever the case, you want to find stocks that are not being fully appreciated by the market with strong growth ahead.
Here are five undervalued stocks you may want to consider. | | Click Here to Download the FREE Report |
|
Markets | | | Inovio stock is essentially flat for the year, and yet INO stockholders have been taken on a wild ride for much longer than that. INO stock has a few potential catalysts that all contain a heightened risk premium which requires investors to have extraordinary patience. Read the Full Story |
|
Politics | | | The Red Sea reefs off the Israeli resort of Eilat host some of the greatest coral diversity on the planet.
A symphony in splendid technicolor, the reefs are among the world’s most resilient coral colonies against warming seas. They have also become an unlikely battleground, caught bet... Read the Full Story |
|
From Our PartnersLike any other investor, I try to buy low and sell high... but the BIG difference with me is that I only buy one kind of stock. 37 of these cash cows are in my portfolio right now... and for every dollar invested in them they are sending us 69 cents in dividends. That's an effective yield of 69% a year-every year. All without leverage, options, or gimmicks. | | Click here to see for yourself. |
|
Politics | | | Global shares slipped Monday amid worries over surging coronavirus infections in Asia as well as concerns about the long-term impact from the Afghan government’s collapse.
France's CAC 40 fell 0.6% in early trading to 27,523.19, while Germany's DAX slipped 0.3% to 15,929.31. Britain's... Read the Full Story |
|
Markets | | | Japan’s economy grew at an annual rate of 1.3% in the last quarter, raising hopes for a gradual recovery from the painful impact of the coronavirus pandemic.
The Cabinet Office reported Monday seasonally adjusted gross domestic product, or GDP, the sum of the value of a nation’s produ... Read the Full Story |
|
Politics | | | India will soon launch a $1.35 trillion national infrastructure plan that will boost the country's economy, Prime Minister Narendra Modi announced Sunday as part of independence day celebrations.
Wearing a flowing bright saffron-colored turban, Modi addressed the nation from New Delhi... Read the Full Story |
|
Markets | | |
High-Flying Cricut, Inc Returns To Earth
Cricut, Inc (NASDAQ: CRCT) caught our attention earlier this year shortly after its IPO. The company's Q1 earnings report was a blowout and opened our eyes to what we see as the new age for crafting. Cricut, Inc provides a range of Internet-connected craft... Read the Full Story |
|
Markets | | | Shares of Disney (NYSE: DIS) look set to end the week on a high as the street digests their Q3 earnings report which was released after Thursday’s session ended. Both the top line and bottom line numbers comfortably beat analyst expectations, with GAAP EPS 60% higher than the consensus and rev... Read the Full Story |
|
The Early Bird Stock Of The Day Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. | | View Today's Stock Pick |
|
